Molly Linn Perencevich, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastroenterology | 5 | 2022 | 577 | 0.870 |
Why?
|
| Fellowships and Scholarships | 4 | 2018 | 1117 | 0.580 |
Why?
|
| Teaching | 2 | 2018 | 1170 | 0.520 |
Why?
|
| Vascular Fistula | 1 | 2013 | 50 | 0.420 |
Why?
|
| Duodenal Diseases | 1 | 2013 | 100 | 0.410 |
Why?
|
| Intestinal Fistula | 1 | 2013 | 142 | 0.400 |
Why?
|
| Ambulatory Care | 1 | 2018 | 2775 | 0.280 |
Why?
|
| Curriculum | 2 | 2018 | 3743 | 0.260 |
Why?
|
| Patient Compliance | 1 | 2013 | 2690 | 0.210 |
Why?
|
| Education, Medical, Graduate | 3 | 2022 | 2373 | 0.200 |
Why?
|
| Faculty, Medical | 3 | 2018 | 1203 | 0.180 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 6935 | 0.180 |
Why?
|
| Colonoscopy | 3 | 2018 | 1394 | 0.180 |
Why?
|
| Career Choice | 1 | 2017 | 756 | 0.180 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 3201 | 0.170 |
Why?
|
| Hospitalists | 1 | 2022 | 294 | 0.160 |
Why?
|
| Colitis, Ulcerative | 2 | 2011 | 1922 | 0.150 |
Why?
|
| Crohn Disease | 2 | 2011 | 2279 | 0.150 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2017 | 1070 | 0.150 |
Why?
|
| Hematemesis | 1 | 2013 | 22 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 935 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2018 | 980 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2006 | 2422 | 0.100 |
Why?
|
| Perception | 1 | 2017 | 1197 | 0.090 |
Why?
|
| Microbiological Techniques | 1 | 2011 | 97 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 6346 | 0.090 |
Why?
|
| Aorta, Abdominal | 1 | 2013 | 625 | 0.090 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 534 | 0.080 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 1972 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2013 | 1834 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 952 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 7407 | 0.070 |
Why?
|
| Workload | 2 | 2017 | 844 | 0.070 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2013 | 874 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2220 | 0.070 |
Why?
|
| Inpatients | 1 | 2017 | 2548 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2013 | 1116 | 0.060 |
Why?
|
| Internet | 1 | 2017 | 3092 | 0.060 |
Why?
|
| Colon | 1 | 2013 | 1792 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2017 | 4792 | 0.060 |
Why?
|
| Diarrhea | 1 | 2011 | 1318 | 0.060 |
Why?
|
| Patient Admission | 1 | 2011 | 1367 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 3889 | 0.050 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2013 | 1228 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 4016 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2011 | 3443 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2017 | 5880 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 58976 | 0.030 |
Why?
|
| Humans | 12 | 2022 | 761504 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 9420 | 0.030 |
Why?
|
| Colectomy | 1 | 2018 | 688 | 0.030 |
Why?
|
| Leadership | 1 | 2022 | 1385 | 0.030 |
Why?
|
| Male | 7 | 2018 | 360804 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 39967 | 0.020 |
Why?
|
| Receptors, Interleukin-1 Type II | 1 | 2011 | 11 | 0.020 |
Why?
|
| Aminohydrolases | 1 | 2011 | 18 | 0.020 |
Why?
|
| Oxo-Acid-Lyases | 1 | 2011 | 22 | 0.020 |
Why?
|
| alpha Karyopherins | 1 | 2011 | 40 | 0.020 |
Why?
|
| Aged | 5 | 2018 | 169289 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 3416 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2011 | 88 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 8002 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2017 | 1254 | 0.020 |
Why?
|
| Middle Aged | 5 | 2018 | 220895 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20570 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 15266 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2017 | 2495 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 1213 | 0.020 |
Why?
|
| Female | 6 | 2018 | 392644 | 0.020 |
Why?
|
| Inflammation | 1 | 2006 | 10773 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3639 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 1342 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 1475 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2011 | 1410 | 0.010 |
Why?
|
| Disease Progression | 1 | 2018 | 13506 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2011 | 4003 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 3448 | 0.010 |
Why?
|
| Risk Factors | 2 | 2018 | 74206 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 13255 | 0.010 |
Why?
|
| Adult | 3 | 2018 | 221177 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 41487 | 0.010 |
Why?
|
| Incidence | 1 | 2011 | 21353 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 54425 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 59243 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 88319 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 26125 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 39106 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 80636 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2011 | 64680 | 0.000 |
Why?
|